Aromatase inhibitors do not increase the risk of deep venous thrombosis; this differs from tamoxifen, for which the risk of deep venous thrombosis and pulmonary embolism is increased approximately twofold (57,58). The gene discussed is CYP19A1; the disease is Venous thrombosis.